A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

R.J. van Geest; S.Y. Lesnik-Oberstein; S. Tan; M. Mura; R. Goldschmeding; C.J.F. van Noorden; I. Klaassen; R.O. Schlingemann

A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

Translated title of the contribution: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

R.J. van Geest, S.Y. Lesnik-Oberstein, S. Tan, M. Mura, R. Goldschmeding, C.J.F. van Noorden, I. Klaassen, R.O. Schlingemann

Department of Pathology

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Original language	Undefined/Unknown
Pages (from-to)	587-590
Number of pages	4
Journal	British Journal of Ophthalmology
Volume	96
Issue number	4
Publication status	Published - 2012

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/22289291

Cite this

van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, S., Mura, M., Goldschmeding, R., van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. British Journal of Ophthalmology, 96(4), 587-590. http://www.ncbi.nlm.nih.gov/pubmed/22289291

@article{db82105d8160430a9c25711352afe401,

title = "A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.",

author = "{van Geest}, R.J. and S.Y. Lesnik-Oberstein and S. Tan and M. Mura and R. Goldschmeding and {van Noorden}, C.J.F. and I. Klaassen and R.O. Schlingemann",

year = "2012",

language = "Undefined/Unknown",

volume = "96",

pages = "587--590",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "BMJ Publishing Group",

number = "4",

}

van Geest, RJ, Lesnik-Oberstein, SY, Tan, S, Mura, M, Goldschmeding, R, van Noorden, CJF, Klaassen, I & Schlingemann, RO 2012, 'A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.', British Journal of Ophthalmology, vol. 96, no. 4, pp. 587-590. <http://www.ncbi.nlm.nih.gov/pubmed/22289291>

A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. / van Geest, R.J.; Lesnik-Oberstein, S.Y.; Tan, S. et al.
In: British Journal of Ophthalmology, Vol. 96, No. 4, 2012, p. 587-590.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

AU - van Geest, R.J.

AU - Lesnik-Oberstein, S.Y.

AU - Tan, S.

AU - Mura, M.

AU - Goldschmeding, R.

AU - van Noorden, C.J.F.

AU - Klaassen, I.

AU - Schlingemann, R.O.

PY - 2012

Y1 - 2012

M3 - Article

SN - 0007-1161

VL - 96

SP - 587

EP - 590

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 4

ER -